Mounjaro vs Zepbound: Same Drug, Different Approvals

If you have searched "Mounjaro vs Zepbound" hoping to find which one is stronger or works better, here is the short answer that almost no marketing page leads with: they are the exact same active drug. Both are tirzepatide, made by the same manufacturer (Eli Lilly), at the same dose strengths, given by the same once-weekly subcutaneous injection. The differences between them are not pharmacological. They are regulatory, financial, and logistical — which FDA indication the brand carries, how insurers treat it, and how the carton is labeled.

The one real difference: the FDA indication

Mounjaro and Zepbound are two brand names for tirzepatide, separated by the condition each is FDA-approved to treat.

Mounjaro is approved as an adjunct to diet and exercise to improve glycemic control in adults — and pediatric patients 10 years of age and older — with type 2 diabetes mellitus¹. That is its lane: blood-sugar control in diabetes.

Zepbound carries the obesity-side approvals. Its label indicates it to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition; and, separately, to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity².

So the genuinely accurate framing of "Mounjaro vs Zepbound" is not "drug A vs drug B." It is "the same molecule wearing two different FDA labels."

Why one molecule has two names at all

This is a deliberate regulatory pattern, not an accident. A manufacturer runs separate clinical-trial programs for separate indications, and the FDA approves each indication on its own evidence. Lilly took tirzepatide through the SURPASS program for type 2 diabetes and the SURMOUNT program for obesity, and the agency cleared each use under a distinct brand.

The diabetes evidence sits under Mounjaro: in the head-to-head SURPASS-2 trial, tirzepatide produced greater reductions in HbA1c (and greater weight loss) than semaglutide 1 mg in adults with type 2 diabetes³. The obesity evidence sits under Zepbound: in the pivotal SURMOUNT-1 trial, tirzepatide reached roughly 21% mean body-weight reduction at the 15 mg dose in adults with obesity who did not have diabetes⁴. Tirzepatide also drove substantial weight loss in people who did have type 2 diabetes in SURMOUNT-2⁵, and Zepbound's newer OSA approval rests on the SURMOUNT-OSA trial, where tirzepatide significantly reduced sleep-apnea severity in adults with obesity⁶. Same drug, three approved problems, two brand names — because that is how the indication-by-indication approval system works.

The shared mechanism explains why one molecule does all of this: tirzepatide is a single peptide that activates both the GIP and the GLP-1 receptor, pathways that act together on the pancreas, appetite centers, and other cardiometabolic tissues⁷. Nothing about that mechanism changes between the Mounjaro carton and the Zepbound carton.

Potency, dosing, and side effects are the same

Because it is the same molecule, the dose ladder is the same. Both brands are titrated through the identical tirzepatide strengths — 2.5, 5, 7.5, 10, 12.5, and 15 mg once weekly — starting low and stepping up to limit nausea. Our tirzepatide dosage chart lays out that schedule, and it applies whether the pen says Mounjaro or Zepbound.

The side-effect profile is identical too: predominantly gastrointestinal — nausea, diarrhea, vomiting, constipation — which are dose-dependent, most common during escalation, and generally mild to moderate. A 10 mg Zepbound dose and a 10 mg Mounjaro dose deliver the same amount of the same drug; there is no "stronger" version. (For what those effects feel like and how long they last, see tirzepatide dosing and side effects.)

This is the single most important myth to retire: nobody is getting a more potent medicine by being on one brand versus the other at the same milligram dose.

What actually differs: insurance, packaging, and price

If the drug is identical, why does the brand matter to you at all? Three practical reasons.

Insurance coverage. This is the big one. Many plans cover Mounjaro for type 2 diabetes but exclude or restrict Zepbound for weight management, because anti-obesity medications are covered far less consistently than diabetes drugs. The brand on the prescription can determine whether your plan pays — even though the molecule is the same. We cover the coverage landscape in does insurance cover Zepbound?.

Packaging and presentation. The two brands ship in their own cartons and labeling, and the available presentations (single-dose pens, single-dose vials, and multi-dose options) are tied to each brand's launch and supply rather than to any difference in the drug.

Price and savings programs. List prices and manufacturer savings offers are set per brand and per indication, so out-of-pocket cost can differ between Mounjaro and Zepbound for the same person. See Zepbound cost and savings for how those programs actually net out.

What does not differ is the storage handling — another tell that this is one drug. Both labels carry word-for-word identical storage instructions: refrigerate at 36–46°F, and an unopened pen or vial can sit unrefrigerated at or below 86°F for up to a total of 21 days¹².

Can you use one off-label for the other's purpose?

In practice, prescribing can cross these lines — for example, Mounjaro prescribed off-label for weight loss in someone without diabetes, or insurance economics pushing a prescriber toward one brand. That is a clinical and coverage decision for your prescriber, not a pharmacological upgrade. Off-label use means using an FDA-approved drug outside its approved indication; it is legal and common, but it is the indication you are crossing, not gaining a different or better medicine. The drug in the syringe is the same tirzepatide either way.

The honest verdict

Mounjaro and Zepbound are the same tirzepatide, at the same doses, with the same mechanism, the same side effects, and the same storage rules. The difference is entirely in the FDA label — Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea — and in the downstream consequences of that label: what your insurance will cover, how the product is packaged, and what it costs. Choose based on your diagnosis, your coverage, and your prescriber's guidance, not on a potency difference that does not exist. For the full picture of what tirzepatide is proven to do, start with our tirzepatide evidence guide; to compare it against the other major incretin drug, see tirzepatide vs semaglutide; for the OSA indication specifically, see Zepbound for sleep apnea; and to weigh providers and access, start with our best tirzepatide overview.